source
- Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launchCompass executives told BioPharma Dive that, if the FDA approves their treatment, they plan to follow the commercial strategy Johnson & Johnson used for its ketamine spray Spravato. When Spravato…
- Novo outlines diversification strategy with new pipeline assets and bolt-on dealsNovo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…